Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | PTPRC | P08575 | 2/20 | 0.40 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29131295 | 0.85 | MAPT (0.45) | LMNATSHRMAPTALDH1A1HPGD | |
| SCHEMBL3196799 | 0.85 | MAPT (0.45) | LMNATSHRMAPTALDH1A1HPGD | |
| SCHEMBL20545052 | 0.85 | CA12 (0.40) | LMNATSHRMAPTALDH1A1PPARG | |
| SCHEMBL3186992 | 0.83 | HDAC1 (0.42) | LMNATSHRMAPTALDH1A1KDM4E | |
| SCHEMBL11368813 | 0.82 | HDAC3 (0.50) | LMNATSHRMAPTALDH1A1TBXAS1 | |
| SCHEMBL3201821 | 0.82 | MAPT (0.42) | LTB4RTSHRMAPTHPGD | |
| SCHEMBL29131269 | 0.81 | LMNA (0.44) | LMNALTB4RPTPRCPTPN13MAPT | |
| SCHEMBL6688879 | 0.80 | HDAC3 (0.47) | LMNATSHRMAPTALDH1A1 | |
| SCHEMBL21946015 | 0.79 | ALDH1A1 (0.48) | LMNATSHRMAPTALDH1A1 | |
| SCHEMBL17045901 | 0.78 | LMNA (0.46) | LMNALTB4RTSHRALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478594-B2 | Methods of treatment of kidney injury associated with infection or trauma | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| US-20220226266-A1 | Methods of Treatment of Kidney Injury Associated with Infection or Trauma | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-07-21 | — | — | US | disclosed |
| WO-2020240524-A2 | METHODS OF TREATMENT OF KIDNEY INJURY ASSOCIATED WITH INFECTION OR TRAUMA | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-12-03 | — | — | WO | disclosed |
| US-20200207691-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | UNIVERSITY OF PITTSBURGH - OF T | 2020-07-02 | — | — | US | disclosed |
| US-20200207691-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | UNIVERSITY OF PITTSBURGH - OF T | 2020-07-02 | — | — | US | disclosed |
| US-10626071-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2020-04-21 | — | — | US | disclosed |
| US-10626071-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2020-04-21 | — | — | US | disclosed |
| US-10160705-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180312455-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10160705-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | HDAC1, HDAC9, HDAC11 | LMNA 1928/4885FAAH 444/4885LTB4R 4082/4885 |
| US-20220226266-A1 | Methods of Treatment of Kidney Injury Associated with Infection or Trauma | MMP8, PLAU, KLKB1 | LMNA 2370/4885FAAH 1121/4885LTB4R 433/4885 |
| US-10626071-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | HDAC1, HDAC9, HDAC11 | LMNA 1928/4885FAAH 444/4885LTB4R 4082/4885 |
| US-20180312455-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | HDAC1, HDAC9, HDAC11 | LMNA 1928/4885FAAH 444/4885LTB4R 4082/4885 |
| US-20200207691-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | HDAC1, HDAC9, HDAC11 | LMNA 1928/4885FAAH 444/4885LTB4R 4082/4885 |
| US-12478594-B2 | Methods of treatment of kidney injury associated with infection or trauma | HDAC1, HDAC2, HDAC4 | LMNA 2466/4885FAAH 526/4885LTB4R 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.